How we make this list: we compare pricing pages, product documentation and public user reviews. Ratings come from G2, Capterra or Trustpilot, with the date we checked them.
What is AI pathology software and who needs it
AI pathology software analyzes whole-slide images of tissue samples to help pathologists detect cancer, grade tumors, score biomarkers and manage case workloads. A lab scans glass slides into gigapixel digital images, and the software flags suspicious regions, counts stained cells, measures tumor areas and ranks cases by urgency. The pathologist keeps the final say on every diagnosis. The software works as a second set of eyes and a productivity aid, not as a replacement for trained judgment.
The buyers are hospital pathology departments, reference laboratories, academic medical centers and pharmaceutical teams running clinical trials. Most buyers already run a digital pathology program with whole-slide scanners, image storage and a laboratory information system. AI sits on top of that stack. A lab that still reads glass slides under a microscope gains little from buying an AI module first, since there is no digital image for the algorithm to read.
Regulatory status shapes every purchase decision in this market. In the United States, only a small number of pathology AI products hold FDA authorization, and each clearance covers a narrow indication, such as prostate core needle biopsies on specific scanners. In Europe, many of the same products carry CE marking under the IVDR for broader diagnostic use. Always confirm the exact clearance for your country and your scanner before signing.
How to choose AI pathology software for your lab
Start with your case mix. A lab that reads mostly prostate biopsies needs a different product than a lab that scores breast cancer biomarkers or runs lung cancer PD-L1 testing. Shortlist vendors whose cleared indications match the tissue types and stains you actually process, then check scanner compatibility, since most clearances name specific scanner models and displays.
Also, price the full program, not the license alone. Scanners, storage, validation studies, training and ongoing quality control usually cost more than the AI subscription. Every vendor in this guide sells on quote, so budget for a sales process and ask for per-slide or per-case pricing in writing before you commit.
The table below summarizes the eight platforms, their strongest use case and their regulatory position as of 21 Nov 2026.
| Tool | Best for | Regulatory position | Starting price |
| Paige | Prostate biopsy AI with FDA authorization | FDA De Novo 2021, CE-IVD | Quote |
| Ibex Medical Analytics | Widely deployed breast and prostate AI | FDA 510(k) 2025, CE-IVDR | Quote |
| Proscia Concentriq | Enterprise digital pathology platform | FDA 510(k) for AP-Dx, CE marked | Quote |
| Aiforia | CE-IVD clinical AI suites in Europe | CE-IVD, research use only in the US | Quote |
| PathAI AISight Dx | FDA-cleared image management for primary diagnosis | FDA 510(k) 2025, CE-IVD | Quote |
| Indica Labs HALO | Quantitative image analysis and research | CE-IVDR for HALO AP, research use only in the US | Quote |
| Visiopharm | Biomarker quantification APPs | IVDR cleared in EU and UK, research use in the US | Quote |
| ArteraAI | Prostate cancer prognosis from slides | FDA De Novo 2025 | Quote |
Quick comparison
| Tool | Best for | Starting price | Free plan |
|---|
Paige | Labs with high prostate biopsy volume that want the first FDA-authorized pathology AI | quote | No free plan; demos and pilots arranged through sales |
Ibex Medical Analytics | Labs that want the most widely deployed clinical AI in pathology, across prostate, breast and gastric cancer | quote | No free plan; evaluation through a sales-led pilot |
Proscia Concentriq | Large labs and health systems moving their whole pathology operation to digital | quote | No free plan; proof of concept available through sales |
Aiforia | European labs that want CE-IVD marked AI suites for breast, lung and prostate cancer | quote | No free plan; demos arranged through sales |
PathAI AISight Dx | Labs that want an FDA-cleared cloud image management system for primary diagnosis with room to add AI apps | quote | No free plan; demos arranged through sales |
Indica Labs HALO | Research and pharma teams that need quantitative, reproducible tissue analysis at scale | quote | No free plan; demos arranged through sales |
Visiopharm | Labs that need standardized biomarker scoring, especially breast and lung cancer panels | quote | No free plan; demos arranged through sales |
ArteraAI | Prostate cancer prognosis and treatment decisions from existing biopsy slides | quote | No free plan; test is ordered by clinicians through an online portal |
Is your product missing or out of date?
We review this list regularly. Vendors can request a listing, send updated pricing or ask about featured placement.
Request a listing
#1
Paige
Best for: Labs with high prostate biopsy volume that want the first FDA-authorized pathology AI
Visit paige.ai
Starting pricequote
Free planNo free plan; demos and pilots arranged through sales
Paige builds AI applications that support cancer detection and diagnosis from whole-slide images, and it holds the first FDA De Novo authorization ever granted for an AI product in pathology. Paige Prostate Detect received that authorization in September 2021 under De Novo number DEN200080, as an adjunct that flags areas of interest on digitized prostate core needle biopsies viewed through the FullFocus viewer. The portfolio now spans prostate, breast, gastrointestinal and PanCancer suites. Tempus acquired Paige in August 2025, so the roadmap now sits inside a genomics-led business. Pricing is sales-led with no public list price. A UK NICE briefing reports indicative pricing from around 1 pound per slide, but that is a third-party figure, not a vendor price, so request a written quote.
What we like- First FDA De Novo authorization for AI pathology
- Broad prostate, breast, GI and PanCancer suites
- Virchow foundation models trained on more than 1.5 million slides
Watch out for- FDA authorization covers only prostate core needle biopsies as an adjunct, so most of the portfolio is not FDA cleared in the United States
- Pricing is unpublished and quoted per case or per slide
#2
Ibex Medical Analytics
Best for: Labs that want the most widely deployed clinical AI in pathology, across prostate, breast and gastric cancer
Visit ibex-ai.com
Starting pricequote
Free planNo free plan; evaluation through a sales-led pilot
Ibex Medical Analytics builds the Galen platform, which its maker describes as the most widely deployed AI technology in pathology. Galen analyzes whole-slide images to detect cancer, grade tumors, score immunohistochemistry markers such as HER2, ER, PR and Ki67, and prioritize the worklist so urgent cases surface first. In Europe, Galen Prostate was the first standalone AI pathology product to receive CE marking under the IVDR, and the breast and gastric suites carry CE-IVDR certification for defined diagnostic indications. In the United States, Galen Second Read received FDA 510(k) clearance in January 2025 under number K241232, while other applications remain research use only. Pricing is quoted per case under an annual agreement, and no list price is published.
What we like- Galen platform is used in routine clinical practice worldwide
- FDA 510(k) clearance for Galen Second Read in January 2025
- CE-IVDR marking across breast, prostate and gastric suites
Watch out for- Regulatory position differs sharply by market, with several applications research use only in the United States
- Pricing is per case and unpublished, so costs scale directly with biopsy volume
#3
Proscia Concentriq
Best for: Large labs and health systems moving their whole pathology operation to digital
Visit proscia.com
Starting pricequote
Free planNo free plan; proof of concept available through sales
Proscia Concentriq is an enterprise digital pathology platform rather than a single AI algorithm, and that breadth is its main selling point. It combines a whole-slide viewer, a configurable worklist, case management, automated storage tiering and bidirectional sync with Epic Beaker and most laboratory information systems. The platform supports more than 45 scanner models and every major image format including DICOM, and it runs about 150 AI applications from partners such as Ibex, Visiopharm, Aiforia and Mindpeak. Concentriq AP-Dx is FDA 510(k) cleared and CE marked for primary diagnosis, while Concentriq AP and Concentriq LS are research use only. Pricing is by contract, with proof-of-concept engagements billed monthly, and no public price list is published.
What we like- Full enterprise platform with viewing, worklist, storage tiering and LIS integration
- Concentriq AP-Dx is FDA 510(k) cleared for primary diagnosis
- Open platform runs about 150 third-party AI apps
Watch out for- Concentriq AP is research use only, so the cleared AP-Dx configuration must be specified in the contract
- Enterprise pricing and implementation are heavy for smaller labs
#4
Aiforia
Best for: European labs that want CE-IVD marked AI suites for breast, lung and prostate cancer
Visit aiforia.com
Starting pricequote
Free planNo free plan; demos arranged through sales
Aiforia provides cloud-based deep learning software for clinical diagnostics and preclinical research, built around a clinical platform that combines a case worklist, an interactive viewer, quantitative AI models and case-level reporting. Its clinical suites cover breast, lung, prostate, colon and gastric cancer, with AI models for tasks such as Gleason grading and HER2 and PD-L1 scoring. Its breast, lung and prostate suites carry CE-IVD marking for diagnostic use in EU and EEA countries. In all other countries the same models are limited to research use only. A distinctive strength is Aiforia Create, which lets pathologists train their own deep learning models without writing code. Pricing follows an annual fee plus usage-based credits, with no published rate card.
What we like- Broadest collection of CE-IVD marked clinical AI models in Europe
- Aiforia Create lets labs build and validate their own models
- Browser-based platform with worklist, viewer and case-level reporting
Watch out for- Outside the EU and EEA, clinical models are research use only with no FDA clearance
- Annual plus usage-based fees make total cost hard to predict before a pilot
#5
PathAI AISight Dx
Best for: Labs that want an FDA-cleared cloud image management system for primary diagnosis with room to add AI apps
Visit pathai.com
Starting pricequote
Free planNo free plan; demos arranged through sales
PathAI AISight Dx is a cloud-native digital pathology image management system that the FDA cleared for primary diagnosis in June 2025 under 510(k) number K243391. The clearance covers viewing and management of digitized surgical pathology slides from formalin-fixed paraffin-embedded tissue, used with Leica Aperio GT 450 DX, Hamamatsu NanoZoomer S360MD and Roche Ventana DP200 and DP600 scanners. A predetermined change control plan lets PathAI add validated scanners, displays and browsers without a new premarket review, which should widen compatibility over time. The broader AISight platform adds automated quality assurance, real-time collaboration, consult workflows and access to third-party AI applications. Pricing is enterprise and quoted per deal, with no public price list, and buyers should budget for scanner validation and storage alongside the license.
What we like- FDA 510(k) clearance for primary diagnosis in June 2025 with a predetermined change control plan
- Cloud-native platform works on standard workstations
- CE-IVD marked for primary diagnosis in the EEA, UK and Switzerland
Watch out for- Clearance applies to named scanners and displays, which limits hardware choice
- Many PathAI AI algorithms remain research use only in the United States
#6
Indica Labs HALO
Best for: Research and pharma teams that need quantitative, reproducible tissue analysis at scale
Visit indicalab.com
Starting pricequote
Free planNo free plan; demos arranged through sales
Indica Labs HALO is the quantitative image analysis platform that many pathology researchers and pharmaceutical teams treat as the default tool for tissue-based measurement. HALO reports morphological and multiplexed expression data on a cell-by-cell basis across whole tissue sections, with an interactive link between cell data and the underlying image. The HALO AI add-on uses deep learning networks for segmentation, classification and phenotyping, and its train-by-example interface lets scientists build custom models without coding. HALO AP provides case-based image management and access to third-party AI through the Aperio AI Store. HALO AP is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK and Switzerland, but it is for research use only in the United States and is not FDA cleared. Pricing is quoted per license, with no public price list published.
What we like- Industry standard for quantitative image analysis, cited in more than 2,000 peer-reviewed publications
- HALO AI lets users train custom models by example
- Unlimited support, training and learning portal access included with every license
Watch out for- HALO AP is research use only in the United States and not FDA cleared for clinical diagnosis
- Licensing is enterprise priced with no published rates
#7
Visiopharm
Best for: Labs that need standardized biomarker scoring, especially breast and lung cancer panels
Visit visiopharm.com
Starting pricequote
Free planNo free plan; demos arranged through sales
Visiopharm builds AI-driven precision pathology software for research and diagnostics from its base in Denmark, and it has been selling image analysis tools for more than two decades. Its diagnostic APPs cover breast cancer markers including HER2, ER, PR and Ki-67, breast and colon metastasis detection, non-small cell lung cancer PD-L1 scoring and prostate Gleason scoring. The company reports nine diagnostic algorithms cleared under IVDR for EU and UK customers, with fully automated zero-click workflows that analyze scanned slides and present results for pathologist review. For research and drug development, the Oncotopix Discovery platform supports tissue mining in multiplexed images and custom analysis. Visiopharm APPs integrate with major image management systems, including Proscia Concentriq and PathAI AISight. Pricing is not published anywhere, so buyers must request a quote.
What we like- Nine diagnostic algorithms cleared under IVDR in the EU and UK
- Zero-click automated workflows that run without manual interaction until pathologist review
- APPs integrate with Proscia Concentriq and PathAI AISight
Watch out for- Diagnostic APPs are not for diagnostic use in the United States
- No published pricing, so cost is only known after a sales conversation
#8
ArteraAI
Best for: Prostate cancer prognosis and treatment decisions from existing biopsy slides
Visit artera.ai
Starting pricequote
Free planNo free plan; test is ordered by clinicians through an online portal
ArteraAI takes a different approach from the other vendors in this guide. Instead of selling software that a lab installs, it sells AI prognostic tests that analyze digital images of a patient existing biopsy slides together with clinical data. The ArteraAI Prostate Test estimates 10-year risk of distant metastasis and prostate cancer specific mortality and predicts which intermediate-risk patients benefit from short-term hormone therapy with radiation. It received FDA De Novo authorization on 31 July 2025 under number DEN240068, establishing a new product category for AI digital pathology risk stratification, and it is included in NCCN guidelines as a prognostic test for prostate cancer. The test uses existing slides, needs no additional staining, and returns results within one to two days of specimen receipt at the company CLIA laboratory. Pricing is per test and covered by Medicare in most cases.
What we like- FDA De Novo authorization in July 2025, the first for AI prostate prognosis
- Included in NCCN guidelines as a prognostic test
- No extra tissue needed, since analysis uses existing H&E slides
Watch out for- Covers only prostate cancer, with a breast test added later and few other cancer types
- Sold as a per-patient test rather than lab software, so it fits a different buying model than the other tools here
What does AI pathology software cost
No vendor in this guide publishes a price list, and that is normal for regulated diagnostic software sold to hospitals. Expect quotes structured as an annual license, a per-slide fee, a per-case fee, or a mix of the three. Aiforia charges an annual platform fee plus usage credits, Ibex and Paige price per case or per slide, Proscia contracts by platform configuration, and ArteraAI charges per test with payer reimbursement. The only public reference point found is a UK NICE briefing that reports Paige pricing from around 1 pound per slide, which is a third-party figure, not a vendor price. Ask each vendor for a written quote that states the pricing unit, the minimum volume, what is included in support, and how prices change as volume grows.
Frequently asked questions
Is AI pathology software FDA approved
Few products hold FDA authorization, and each one covers a narrow indication. Paige Prostate Detect holds a De Novo authorization from September 2021 for prostate core needle biopsies. Ibex Galen Second Read holds a 510(k) clearance from January 2025. PathAI AISight Dx holds a 510(k) clearance from June 2025 for primary diagnosis on named scanners. ArteraAI Prostate holds a De Novo authorization from July 2025 for prostate prognosis. Proscia Concentriq AP-Dx and Indica Labs HALO AP Dx also hold FDA clearance for primary diagnosis workflows. Always check the clearance for the exact product and scanner you plan to use.
Can AI pathology software replace a pathologist
No. Every product in this guide is designed to assist pathologists, not to replace them. The software flags suspicious regions, counts stained cells, scores biomarkers and prioritizes the worklist, but the pathologist reviews the slide and signs the report. FDA clearances in this field are granted for adjunct use or for viewing and management systems, and the final diagnosis stays with a qualified human.
What is the difference between CE-IVD and FDA clearance
CE-IVD marking means a product meets European Union in-vitro diagnostic rules and can be used for diagnosis in the EU and EEA. FDA clearance means the United States Food and Drug Administration has reviewed the product for a specific indication. Many pathology AI products carry CE-IVD marking in Europe while remaining research use only in the United States, so a product that is cleared for diagnosis in one market may not be cleared in another.
Do I need a digital pathology program before buying AI
Yes, in almost every case. AI pathology software analyzes whole-slide images, so your lab needs scanners, image storage, a viewer and a laboratory information system connection first. Vendors sell AI as an add-on to that stack, and several clearances require specific scanner models and displays. A lab that still reads glass slides should budget for scanning and storage before evaluating AI.
How long does it take to deploy AI pathology software
Expect three to twelve months from contract to routine use. Installation and integration usually take weeks, but validation takes longer, since the lab must run the AI on its own archived cases, compare results with the original diagnoses, and document performance for accreditation. Training pathologists and building quality control processes adds further time, and validation work cannot be skipped.
Sources we checked (15)
- https://www.paige.ai
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?id=DEN200080
- https://ibex-ai.com
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K241232
- https://proscia.com/solutions/clinical
- https://www.aiforia.com/clinical-platform
- https://www.aiforia.com/aiforia-clinical-solutions
- https://www.pathai.com/aisightdx-digital-pathology-solution
- https://fda.innolitics.com/device/K243391
- https://indicalab.com/halo/
- https://indicalab.com/clinical-products/halo-prostate-ai/
- https://visiopharm.com
- https://www.artera.ai
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN240068
- https://healthcaresolutions-us.fujifilm.com/resources/press-release/fujifilm-announces-asset-purchase-agreement-with-inspirata-inc-to-acquire-the-companys-digital-pathology-business/
Is your product missing or out of date?
We review this list regularly. Vendors can request a listing, send updated pricing or ask about featured placement.
Request a listing
Shihab Mia · Founder, Rankite
Shihab has 5+ years in B2B and SaaS SEO. He writes Rankite's software buying guides from pricing pages, documentation and public user reviews. More about Shihab.